GeorgeNathanielMagrathIIIMDMBA
Ophthalmology • Charleston, SCOcular Oncology
Assistant Professor of Ophthalmology
Dr. Magrath is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
171 Ashley Ave
Charleston, SC 29425Phone+1 843-792-1414
Education & Training
Medical University of South CarolinaResidency, Ophthalmology, 2011 - 2014- Medical University of South Carolina College of MedicineInternship, Transitional Year, 2010 - 2011
- Medical University of South CarolinaClass of 2010
Certifications & Licensure
SC State Medical License 2011 - 2025
PA State Medical License 2014 - 2016- American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- Fellow (FACS) American College of Surgeons
Clinical Trials
- Study to Evaluate the Safety and Efficacy of Topical Minocycline Gel in Patients With Papulopustular Rosacea Start of enrollment: 2017 Oct 30
Publications & Presentations
PubMed
- 253 citationsCORRELATION OF FOVEAL AVASCULAR ZONE SIZE WITH FOVEAL MORPHOLOGY IN NORMAL EYES USING OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY.Wasim A. Samara, Emil Anthony T. Say, Chloe T.L. Khoo, Timothy Patrick Higgins, George N. Magrath
Retina. 2015-11-01 - 97 citationsVARIABILITY IN FOVEAL AVASCULAR ZONE AND CAPILLARY DENSITY USING OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY MACHINES IN HEALTHY EYES.George N. Magrath, Emil Anthony T. Say, Kareem Sioufi, Sandor R. Ferenczy, Wasim A. Samara
Retina. 2017-11-01 - 172 citationsGlobal Retinoblastoma Presentation and Analysis by National Income LevelIdo Didi Fabian, Elhassan Abdallah, Shehu U. Abdullahi, Rula A. Abdulqader, Sahadatou Adamou Boubacar
JAMA Oncology. 2020-05-01
Press Mentions
Ocuphire Acquires Gene Therapy Company Opus GeneticsOctober 22nd, 2024- How AI Can Be Used to Help People SeeDecember 17th, 2022
- Ocuphire Pharma Receives FDA Agreement for Phase 3 Trial of Phentolamine Solution for the Treatment of Decreased Visual Acuity Under Dim Light ConditionsJanuary 6th, 2024
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
